Top

BMC Nephrology

Published in:

01-12-2020 | Escherichia Coli | Research article

Fecal microbiota characteristics of Chinese patients with primary IgA nephropathy: a cross-sectional study

Authors: Xiaofang Hu, Jie Du, Yuhong Xie, Qiong Huang, Yi Xiao, Juan Chen, Siyuan Yan, Zhicheng Gong, Shaxi Ouyang

Published in: BMC Nephrology | Issue 1/2020

Abstract

Background

Growing evidence has shown that the gut-renal connection and gut microbiota dysbiosis play a critical role in immunoglobulin A nephropathy (IgAN). However, the fecal microbiome profile in Chinese patients with IgAN remains unknown. A cross-sectional study was designed for the first time to investigate the fecal microbiota compositions in patients with primary IgAN in China and to evaluate the relationship between the fecal microbiome and IgAN clinical presentation.

Methods

Fecal samples were collected from 17 IgAN patients and 18 age-, sex-, and body mass index-matched healthy controls, and bacterial DNA was extracted for 16S ribosomal RNA gene sequencing targeting the V3-V4 region.

Results

Fecal samples from the IgAN patients and healthy controls showed differences in gut microbiota community richness and compositions. Compared to the healthy controls, IgAN patients at the phylum level had an increased abundance of Fusobacteria, but a decreased abundance of Synergistetes. The significantly increased genera in the IgAN group were Escherichia-Shigella, Hungatella, and Eggerthella, all of which possess pathogenic potential. Furthermore, the genus Escherichia-Shigella was negatively associated with the estimated glomerular filtration rate (eGFR) but was positively associated with the urinary albumin-to-creatinine ratio (uACR). However, the genus rectale_group was present in the IgAN group with a low abundance and was negatively associated with the uACR. Functional analysis disclosed that infection-related pathways were enriched in the IgAN group.

Conclusions

We demonstrate that gut microbiota dysbiosis occurs in patients with IgAN, and that changes in gut bacterial populations are closely related to IgAN clinical features, suggesting that certain specific gut microbiota may be a potential therapeutic target for IgAN.

Available only for authorised users

Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402–14. https://doi.org/10.1056/NEJMra1206793.CrossRefPubMed

McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414–30. https://doi.org/10.1093/ndt/gfq665..CrossRefPubMed

De Zhou F, Zhao MH, Zou WZ, Liu G, Wang H. The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese Centre. Nephrol Dial Transplant. 2009;24(3):870–6. https://doi.org/10.1093/ndt/gfn554.CrossRefPubMed

Yu H-H, Chiang B-L. Diagnosis and classification of IgA nephropathy. Autoimmun Rev 2014;13(4):556–559. doi:https://doi.org/https://doi.org/10.1016/j.autrev.2014.01.030.

Huang C, Li X, Wu J, et al. The landscape and diagnostic potential of T and B cell repertoire in immunoglobulin a nephropathy. J Autoimmun 2019;97:100–107. doi:https://doi.org/https://doi.org/10.1016/j.jaut.2018.10.018.

D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36(2):227–37. https://doi.org/10.1053/ajkd.2000.8966.CrossRefPubMed

Lai KN, Tang SCW, Schena FP, et al. IgA nephropathy. Nat Rev Dis Prim 2016;2:16001. https://doi.org/https://doi.org/10.1038/nrdp.2016.1.

Nakajima A, Vogelzang A, Maruya M, et al. IgA regulates the composition and metabolic function of gut microbiota by promoting symbiosis between bacteria. J Exp Med 2018;215(8):2019–2034. http://dx.doi.org/https://doi.org/10.1084/jem.20180427.

Catanzaro JR, Strauss JD, Bielecka A, et al. IgA-deficient humans exhibit gut microbiota dysbiosis despite secretion of compensatory IgM. Sci Rep. 2019;9(1):13574. https://doi.org/10.1038/s41598-019-49923-2.

10.

Floege J, Feehally J. The mucosa-kidney axis in IgA nephropathy. Nat Rev Nephrol. 2016;12(3):147–56. https://doi.org/10.1038/nrneph.2015.208.

11.

Evenepoel P, Poesen R, Meijers B. The gut–kidney axis. Pediatr Nephrol. 2017;32(11):1–10.CrossRef

12.

Olive C, Allen AC, Harper SJ, Wicks ACB, Feehally J, Falk MC. Expression of the mucosal y T cell receptor V region repertoire in patients with IgA nephropathy. Kidney Int. 1997;52(4):1047–53. https://doi.org/10.1038/ki.1997.427.CrossRefPubMed

13.

Mccarthy DD, Julie K, Cheryl W, et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest. 2011;121(10):3991.CrossRef

14.

Felizardo RJF, Castoldi A, Andrade-Oliveira V, Câmara NOS. The microbiota and chronic kidney diseases: a double-edged sword. Clin Transl Immunol. 2016;5(6):e86. https://doi.org/10.1038/cti.2016.36.CrossRef

15.

Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187–96. https://doi.org/10.1038/ng.3118.

16.

Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2015;31(1):69–75.CrossRef

17.

Forbes JD, Van Domselaar G, Bernstein CN. The gut microbiota in immune-mediated inflammatory diseases. Front Microbiol. 2016;7(undefined):1081. https://doi.org/10.3389/fmicb.2016.01081.

18.

Xinyun Q, Mingming Z, Xiaotong Y, Na H, Chenggong Y. Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J Crohn S Colitis. 2013;7(11):e558–68.CrossRef

19.

Grosserichter-Wagener C, Radjabzadeh D, van der Weide H, et al. Differences in systemic IgA reactivity and circulating Th subsets in healthy volunteers with specific microbiota enterotypes. Front Immunol. 2019;10(undefined):341. https://doi.org/10.3389/fimmu.2019.00341.

20.

Wortelboer K, Nieuwdorp M, Herrema H. Fecal microbiota transplantation beyond Clostridioides difficile infections. EBioMedicine. 2019;44:716–29. https://doi.org/10.1016/j.ebiom.2019.05.066.CrossRefPubMedPubMedCentral

21.

De Angelis M, Montemurno E, Piccolo M, et al. Microbiota and metabolome associated with Immunoglobulin A Nephropathy (IgAN). PLoS One. 2014;9(6):e99006. https://doi.org/10.1371/journal.pone.0099006.

22.

Escobar JS, Klotz B, Valdes BE, Agudelo GM. The gut microbiota of Colombians differs from that of Americans, Europeans and Asians. BMC Microbiol. 2014;14:311. https://doi.org/10.1186/s12866-014-0311-6.CrossRefPubMedPubMedCentral

23.

Lerman J. Study design in clinical research: sample size estimation and power analysis. Can J Anaesth 1996;43(2):184–191. http://dx.doi.org/https://doi.org/10.1007/BF03011261.

24.

Faul F, Erdfelder E, Lang A-G, Buchner A. G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39(2):175–191. http://dx.doi.org/https://doi.org/10.3758/bf03193146.

25.

Xianglei K, Yingchun M, Jianghua C, et al. Evaluation of the chronic kidney disease epidemiology collaboration equation for estimating glomerular filtration rate in the Chinese population. Nephrol Dial Transplant. 2013;28(3):641–51.CrossRef

26.

Aßhauer KP, Wemheuer B, Daniel R, Meinicke P. Tax4Fun: predicting functional profiles from metagenomic 16S rRNA data. Bioinformatics. 2015;31(17):2882–4. https://doi.org/10.1093/bioinformatics/btv287.CrossRefPubMedPubMedCentral

27.

Collin P, Syrjänen J, Partanen J, Pasternack A, Kaukinen K, Mustonen J. Celiac disease and HLA DQ in patients with IgA nephropathy. Am J Gastroenterol. 2002;97(10):2572–6.CrossRef

28.

Adina W, Birgitta S, Michael F, Ludvigsson JF. Increased risk of IgA nephropathy among individuals with celiac disease. J Clin Gastroenterol. 2013;47(8):678–83.CrossRef

29.

Helin H, Mustonen J, Reunala T, Pasternack A. IgA nephropathy associated with celiac disease and dermatitis herpetiformis. Arch Pathol Lab Med. 1983;107(6):324–7.PubMed

30.

Donaldson GP, Ladinsky MS, Yu KB, et al. Gut microbiota utilize immunoglobulin A for mucosal colonization. Science .2018;360:795–800. http://dx.doi.org/https://doi.org/10.1126/science.aaq0926.

31.

Tanya Y, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–7.CrossRef

32.

Gentile CL, Weir TL. The gut microbiota at the intersection of diet and human health. Science. 2018;362(6416):776–80.

33.

Kothari A, Fulcher CA, Weaver DS, et al. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res. 2015;44(D1):D471–80. https://doi.org/10.1093/nar/gkv1164.CrossRefPubMedPubMedCentral

34.

Pan X, Xue F, Nan X, et al. Illumina sequencing approach to characterize thiamine metabolism related Bacteria and the impacts of thiamine supplementation on Ruminal microbiota in dairy cows fed high-grain diets. Front Microbiol. 2017;8:1818. https://doi.org/10.3389/fmicb.2017.01818.CrossRefPubMedPubMedCentral

35.

Kunisawa J, Sugiura Y, Wake T, et al. Mode of bioenergetic metabolism during B cell differentiation in the intestine determines the distinct requirement for vitamin B₁. Cell Rep. 2015;13(1):122–31. https://doi.org/10.1016/j.celrep.2015.08.063.CrossRefPubMed

36.

Kunisawa J. Metabolic changes during B cell differentiation for the production of intestinal IgA antibody. Cell Mol Life Sci. 2017;74(8):1503–9. https://doi.org/10.1007/s00018-016-2414-8.CrossRefPubMed

37.

Huggan PJ, Murdoch DR. Fusobacterial infections: clinical spectrum and incidence of invasive disease. J Inf Secur. 2008;57(4):283–9. https://doi.org/10.1016/j.jinf.2008.07.016.CrossRef

38.

Manson McGuire A, Cochrane K, Griggs AD, et al. Evolution of invasion in a diverse set of Fusobacterium species. MBio. 2014;5(6):e01864. https://doi.org/10.1128/mBio.01864-14.

39.

Shin N-R, Whon TW, Bae J-W. <em>Proteobacteria</em>: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015;33(9):496–503. https://doi.org/10.1016/j.tibtech.2015.06.011.CrossRefPubMed

40.

Lupp C, Robertson ML, Wickham ME, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe. 2007;2(3):204. https://doi.org/10.1016/j.chom.2007.08.002.CrossRefPubMed

41.

Xu K-Y, Xia G-H, Lu J-Q, et al. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients. Sci Rep. 2017;7(1):1445. https://doi.org/10.1038/s41598-017-01387-y.CrossRefPubMedPubMedCentral

42.

Wang F, Jiang H, Shi K, Ren YI, Zhang P, Cheng S. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology. 2012;17(8):733–8. https://doi.org/10.1111/j.1440-1797.2012.01647.x.CrossRefPubMed

43.

Zhang J, Guo Z, Xue Z, et al. A phylo-functional core of gut microbiota in healthy young Chinese cohorts across lifestyles, geography and ethnicities. Isme J 2015;9:1979. https://doi.org/https://doi.org/10.1038/ismej.2015.11.

44.

Weiss GA, Chassard C, Hennet T. Selective proliferation of intestinal Barnesiella under fucosyllactose supplementation in mice. Br J Nutr. 2014;111(9):1602–10. https://doi.org/10.1017/S0007114513004200.CrossRefPubMed

45.

Gomez A, Luckey D, Yeoman CJ, et al. Loss of sex and age driven differences in the gut microbiome characterize arthritis-susceptible 0401 mice but not arthritis-resistant 0402 mice. PLoS One. 2012;7(4):e36095. https://doi.org/10.1371/journal.pone.0036095.

46.

Wylie KM, Truty RM, Sharpton TJ, et al. Novel bacterial taxa in the human microbiome. PLoS One. 2012;7(6):e35294.CrossRef

47.

Mancabelli L, Milani C, Lugli GA, Turroni F, Ventura M. Identification of universal gut microbial biomarkers of common human intestinal diseases by meta-analysis. Fems Microbiol Ecol. 2017;93(12):fix153. https://doi.org/10.1093/femsec/fix153.

48.

Sakamoto M, Takagaki A, Matsumoto K, Kato Y, Goto K, Benno Y. Butyricimonas synergistica gen. Nov., sp. nov. and Butyricimonas virosa sp. nov., butyric acid-producing bacteria in the family ‘Porphyromonadaceae’ isolated from rat faeces. Int J Syst Evol Microbiol. 2009;59(7):1748–53 https://ijs.microbiologyresearch.org/content/journal/ijsem/10.1099/ijs.0.007674-0.CrossRef

49.

Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease- and Uricase-containing, Indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230–7. https://doi.org/10.1159/000360010.CrossRefPubMedPubMedCentral

50.

Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83(2):308–15.CrossRef

51.

Schulthess J, Pandey S, Capitani M, et al. The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages. Immunity. 2019;50(2):432–45.e7. https://doi.org/10.1016/j.immuni.2018.12.018.CrossRefPubMedPubMedCentral

52.

Forbes JD, Chen C-Y, Knox NC, et al. A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist? Microbiome. 2018;6(1):221. https://doi.org/10.1186/s40168-018-0603-4.

53.

Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60. http://dx.doi.org/https://doi.org/10.1038/nature11450.

54.

Chen J, Wright K, Davis JM, et al. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med 2016;8(1):43. http://dx.doi.org/https://doi.org/10.1186/s13073-016-0299-7.

55.

Thota VR, Dacha S, Natarajan A, Nerad J. Eggerthella lenta bacteremia in a Crohn’s disease patient after ileocecal resection. Future Microbiol 2011;6(5):595–597. http://dx.doi.org/https://doi.org/10.2217/fmb.11.31.

56.

Morales P, Fujio S, Navarrete P, et al. Impact of dietary lipids on colonic function and microbiota: an experimental approach involving Orlistat-induced fat Malabsorption in human volunteers. Clin Transl Gastroenterol. 2016;7(4):e161.CrossRef

57.

Jiang S, Xie S, Lv D, et al. Alteration of the gut microbiota in Chinese population with chronic kidney disease. Sci Rep. 2017;7(1):2870. https://doi.org/10.1038/s41598-017-02989-2.CrossRefPubMedPubMedCentral

58.

Mir RA, Kudva IT. Antibiotic-resistant Shiga toxin-producing Escherichia coli: an overview of prevalence and intervention strategies. Zoonoses Public Health. 2019;66(1):1–13. https://doi.org/10.1111/zph.12533.CrossRefPubMed

59.

Rostoker G, Wirquin V, Terzidis H, et al. Mucosal immunity in primary glomerulonephritis. Nephron. 1993;63(3):286–90. https://doi.org/10.1159/000187211.CrossRefPubMed

60.

Chassaing B, Koren O, Carvalho FA, Ley RE, Gewirtz AT. AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition. Gut. 2014;63(7):1069–80. https://doi.org/10.1136/gutjnl-2013-304909.

61.

Flannigan KL, Taylor MR, Pereira SK, et al. An intact microbiota is required for the gastrointestinal toxicity of the immunosuppressant mycophenolate mofetil. J Hear Lung Transplant. 2018;37(9):1047–59. https://doi.org/10.1016/j.healun.2018.05.002.

62.

Liu P, Lassén E, Nair V, et al. Transcriptomic and proteomic profiling provides insight into Mesangial cell function in IgA nephropathy. J Am Soc Nephrol. 2017;28(10):2961–72. https://doi.org/10.1681/ASN.2016101103.CrossRefPubMedPubMedCentral

63.

Fan JM, Liu XR, Zhong X, Ma XY, Zhang YJ, Qin W. External suppression causes the low expression of the Cosmc gene in IgA nephropathy. Nephrol Dial Transplant. 2008;23(5):1608–14. https://doi.org/10.1093/ndt/gfm781.CrossRefPubMed

64.

Coppo R, Camilla R, Amore A, et al. Toll-like receptor 4 expression is increased in circulating mononuclear cells of patients with immunoglobulin a nephropathy. Clin Exp Immunol. 2010;159(1):73–81. https://doi.org/10.1111/j.1365-2249.2009.04045.x.CrossRefPubMedPubMedCentral

65.

Donadio ME, Loiacono E, Peruzzi L, et al. Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch--Schönlein purpura and primary IgA nephropathy. Pediatr Nephrol. 2014;29(9):1545–51. https://doi.org/10.1007/s00467-014-2807-6.CrossRefPubMed

66.

Meijers B, Jouret F, Evenepoel P. Linking gut microbiota to cardiovascular disease and hypertension: Lessons from chronic kidney disease. Pharmacol Res. 2018;133(undefined):101–7. https://doi.org/10.1016/j.phrs.2018.04.023.

Title: Fecal microbiota characteristics of Chinese patients with primary IgA nephropathy: a cross-sectional study
Authors: Xiaofang Hu
Jie Du
Yuhong Xie
Qiong Huang
Yi Xiao
Juan Chen
Siyuan Yan
Zhicheng Gong
Shaxi Ouyang
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Escherichia Coli
Respiratory Microbiota
Published in: BMC Nephrology / Issue 1/2020
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-020-01741-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Left-ventricular diastolic dysfunction in Korean children with chronic kidney disease: data from the KNOW-Ped CKD study

Climate change causes changes in biochemical markers of kidney disease

The effect of BCM guided dry weight assessment on short-term survival in Chinese hemodialysis patients

Intradialytic complications among patients on twice-weekly maintenance hemodialysis: an experience from a hemodialysis center in Eritrea

Design and methods of the prevalence and pharmacogenomics of tenofovir nephrotoxicity in HIV-positive adults in south-western Nigeria study

Psychological characteristics and associations between living kidney transplantation recipients and biologically related or unrelated donors

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage